MX2019014489A - Programa de dosificacion para tesetaxel y capecitabina. - Google Patents

Programa de dosificacion para tesetaxel y capecitabina.

Info

Publication number
MX2019014489A
MX2019014489A MX2019014489A MX2019014489A MX2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A
Authority
MX
Mexico
Prior art keywords
capecitabine
tesetaxel
dosing schedule
patient
cancer
Prior art date
Application number
MX2019014489A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Tang
Thomas Wei
Stew Kroll
John G Lemkey
Steven Pfeiffer
Jeff Vacirca
Original Assignee
Odonate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odonate Therapeutics Inc filed Critical Odonate Therapeutics Inc
Publication of MX2019014489A publication Critical patent/MX2019014489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019014489A 2017-06-02 2018-06-01 Programa de dosificacion para tesetaxel y capecitabina. MX2019014489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514483P 2017-06-02 2017-06-02
PCT/US2018/035653 WO2018223029A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Publications (1)

Publication Number Publication Date
MX2019014489A true MX2019014489A (es) 2020-08-17

Family

ID=64455637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014489A MX2019014489A (es) 2017-06-02 2018-06-01 Programa de dosificacion para tesetaxel y capecitabina.

Country Status (14)

Country Link
US (1) US20200179427A1 (cg-RX-API-DMAC10.html)
EP (1) EP3630091A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020522568A (cg-RX-API-DMAC10.html)
KR (1) KR20200014880A (cg-RX-API-DMAC10.html)
CN (1) CN111032035A (cg-RX-API-DMAC10.html)
AU (1) AU2018275122A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019025164A2 (cg-RX-API-DMAC10.html)
CA (1) CA3065783A1 (cg-RX-API-DMAC10.html)
EA (1) EA201992852A1 (cg-RX-API-DMAC10.html)
IL (1) IL270973A (cg-RX-API-DMAC10.html)
MA (1) MA50039A (cg-RX-API-DMAC10.html)
MX (1) MX2019014489A (cg-RX-API-DMAC10.html)
TW (1) TW201902473A (cg-RX-API-DMAC10.html)
WO (1) WO2018223029A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019359755A1 (en) * 2018-10-17 2021-05-20 Odonate Therapeutics, Inc. Methods of treating CNS tumors with tesetaxel
TW202112364A (zh) * 2019-08-16 2021-04-01 美商蜻蛉治療股份有限公司 投與替司他賽(tesetaxel)與cyp3a4誘導劑之糖皮質素之方法
WO2022177835A1 (en) * 2021-02-16 2022-08-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201701880A (zh) * 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法

Also Published As

Publication number Publication date
MA50039A (fr) 2020-07-08
JP2020522568A (ja) 2020-07-30
KR20200014880A (ko) 2020-02-11
AU2018275122A1 (en) 2019-12-19
CA3065783A1 (en) 2018-12-06
EA201992852A1 (ru) 2020-03-27
BR112019025164A2 (pt) 2020-06-16
WO2018223029A1 (en) 2018-12-06
US20200179427A1 (en) 2020-06-11
CN111032035A (zh) 2020-04-17
TW201902473A (zh) 2019-01-16
EP3630091A1 (en) 2020-04-08
EP3630091A4 (en) 2021-03-10
IL270973A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2020006668A (es) Anticuerpos para lilrb2.
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2019003938A (es) Compuestos espirociclicos.
GEP20217331B (en) Anti-tigit antibodies
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12016501411A1 (en) Bifunctional cytotoxic agents
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
MX2023012451A (es) Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MY178726A (en) Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
MX377729B (es) Métodos para tratamiento del melanoma.
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2017016353A (es) Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
MX2019002925A (es) Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2017014436A (es) Compuestos biciclicos.
MX379622B (es) Compuestos espirociclicos